Haemonetics (HAE) Tops Q1 EPS by 1c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $127.42 +5.94%
Revenue Growth %: +5.6%
Financial Fact:
Income before provision for income taxes: 22.83M
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: +5.6%
Financial Fact:
Income before provision for income taxes: 22.83M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q1 EPS of $1.02, $0.01 better than the analyst estimate of $1.01. Revenue for the quarter came in at $336.17 million versus the consensus estimate of $335.05 million.
GUIDANCE:
Haemonetics sees FY2025 EPS of $4.45-$4.75, versus the consensus of $4.60.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Enact Holdings (ACT) Reports In-Line Q3 EPS
- PureCycle Technologies, Inc. (PCT) Tops Q3 EPS by 25c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
